02591.HK
Guangzhou Innogen Pharmaceutl Grp Co Ltd
HKSE · Healthcare · Biotechnology · CN
HKD 3.40
+3.98%Year over year
Reported trailing growth
- Revenue
- +172.9%
- EBITDA
- -52.1%
- EBIT
- -62.6%
- EPS
- -45.1%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- -76.3%
- Net income
- -90.4%
- EPS
- -100.0%
- Free cash flow
- -90.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026